Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29959330 | 1.00 | KCNA3 (0.33) | KCNA3CYP2A6 | |
| SCHEMBL17822179 | 0.71 | PIK3CA (0.47) | — | |
| SCHEMBL25822955 | 0.69 | CCR1 (0.33) | CYP2A6 | |
| SCHEMBL25822909 | 0.65 | CYP2A6 (0.43) | CYP2A6 | |
| SCHEMBL23218344 | 0.65 | CYP2A6 (0.32) | KCNA3CYP2A6 | |
| SCHEMBL4264988 | 0.65 | CYP2A6 (0.47) | KCNA3CYP2A6 | |
| SCHEMBL12137043 | 0.63 | GPR35 (0.32) | CYP2A6 | |
| SCHEMBL11985866 | 0.63 | TDP1 (0.35) | — | |
| SCHEMBL19296324 | 0.63 | CYP2A6 (0.32) | CYP2A6 | |
| SCHEMBL4420462 | 0.62 | CYP2A6 (0.41) | KCNA3CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240199637-A1 | IMPROVED PROCESS FOR THE PREPARATION OF 7-(MORPHOLINYL)-2-(N-PIPERAZINYL)METHYLTHIENO[2, 3-C]PYRIDINE DERIVATIVES | NATCO PHARMA LIMITED (IN) | 2024-06-20 | — | — | US | disclosed |
| EP-4326276-A1 | IMPROVED PROCESS FOR THE PREPARATION OF 7-(MORPHOLINYL)-2-(N-PIPERAZINYL)METHYLTHIENO[2, 3-C]PYRIDINE DERIVATIVES | Natco Pharma Ltd (IN) | 2024-02-28 | — | — | EP | disclosed |
| CN-117529325-A | Improved process for preparing 7- (morpholinyl) -2- (N-piperazinyl) methylthio [2,3-c ] pyridine derivatives | 纳特科药品有限公司 | 2024-02-06 | — | — | CN | disclosed |
| CN-107074873-B | 7- (morpholinyl) -2- (N-piperazinyl) methylthioeno [2, 3-c ] pyridine derivatives as anticancer agents | 纳科法尔马有限公司 | 2022-01-07 | — | — | CN | disclosed |
| EP-3230289-B1 | 7-(MORPHOLINYL)-2-(N-PIPERAZINYL) METHYL THIENO [2, 3-C]PYRIDINE DERIVATIVES AS ANTICANCER DRUGS | NATCO PHARMA LTD (IN) | 2019-08-14 | — | — | EP | disclosed |
| US-20170320891-A1 | 7-(MORPHOLINYL)-2-(N-PIPERAZINYL) METHYL THIENO [2, 3-C] PYRIDINE DERIVATIVES AS ANTICANCER DRUGS | NATCO PHARMA LIMITED (IN) | 2017-11-09 | — | — | US | disclosed |
| US-20170320891-A1 | 7-(MORPHOLINYL)-2-(N-PIPERAZINYL) METHYL THIENO [2, 3-C] PYRIDINE DERIVATIVES AS ANTICANCER DRUGS | NATCO PHARMA LIMITED (IN) | 2017-11-09 | — | — | US | disclosed |
| WO-2016092556-A1 | 7-(MORPHOLINYL)-2-(N-PIPERAZINYL) METHYL THIENO [2, 3-C] PYRIDINE DERIVATIVES AS ANTICANCER DRUGS | NATCO PHARMA LIMITED (IN) | 2016-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199637-A1 | IMPROVED PROCESS FOR THE PREPARATION OF 7-(MORPHOLINYL)-2-(N-PIPERAZINYL)METHYLTHIENO[2, 3-C]PYRIDINE DERIVATIVES | NR2C2, NRDC, NDC1 | KCNA3 1667/4885CYP2A6 656/4885 |
| US-20170320891-A1 | 7-(MORPHOLINYL)-2-(N-PIPERAZINYL) METHYL THIENO [2, 3-C] PYRIDINE DERIVATIVES AS ANTICANCER DRUGS | PRMT7, CDK7, CASP7 | KCNA3 2202/4885CYP2A6 1903/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.